Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ataluren · PTC-124

Small molecule · developed by PTC Therapeutics

Phase 3 Most advanced trial
PTCT Developer
2 Registered trials

What is Ataluren?

Ataluren (PTC124, Translarna) is a drug studied in colorectal cancer, endometrial cancer and Duchenne muscular dystrophy.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PTC-124, Translarna
Drug type
Small molecule
Therapy area
Musculoskeletal, Oncology
Developer
PTC Therapeutics (PTCT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
K16AME9I3V

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01247207 Phase 3 Duchenne Muscular Dystrophy Terminated PTCT
NCT04014530 Phase 1/2 Colorectal Cancer Recruiting PTCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Colorectal CancerEndometrium CancerDuchenne Muscular Dystrophy

More from PTC Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.

Follow PTCT, the company behind Ataluren

See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.